Related Experiment Video
Updated: May 13, 2025
Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023
Serological Responses and Pregnancy Outcomes in Women With Serofast Syphilis: Efficacy of Retreatment in a
Rui-Lin Yan1, Ying Xu1, Jing Tong2
1Department of Prevention and Control of Sexually Transmitted Diseases and Leprosy, Shenzhen Baoan Center for Chronic Disease Control, Shenzhen, China.
Background:
There are inconsistencies in guidelines concerning the necessity for anti-syphilis retreatment during pregnancy for women who tested seropositive despite having received treatment before pregnancy. While global guidelines indicate that no further treatment is necessary, Chinese guidelines advocate for an additional treatment course.
Methods:
A prospective nested case-control study was conducted to analyze serological responses and pregnancy outcomes in women with serofast syphilis, focusing on the effects of retreatment.
Results:
Of 584 women with serofast syphilis, 537 (92.0%) experienced normal pregnancy outcomes, comparable to the 93.6% in women without syphilis. However, 47 (8.0%) faced adverse pregnancy outcomes (APOs), which included 8 (1.4%) spontaneous abortions, 2 (0.3%) intrauterine fetal deaths, and 37 (6.3%) instances of preterm birth or low birth weight. The rate of APOs showed no significant difference between those treated with benzathine penicillin G and those who were not (adjusted odds ratio [aOR], 0.59 [95% confidence interval {CI}, .31-1.14]; P = .118). Among 462 newborns with follow-up, no congenital syphilis cases were identified. Serological responses were evaluated in 568 women, revealing that 74 (13.0%) experienced seroreversion of nontreponemal antibodies, 52 (9.2%) had a ≥4-fold decrease in titers, 6 (1.0%) had a ≥4-fold increase in titers, and 436 (74.7%) maintained stable titers. No significant difference in seroreversion rate was found between the retreated and non-retreated groups (aOR, 1.43 [95% CI, .76-2.71]; P = .271).
Conclusions:
With adequate prenatal care and continuous monitoring of serological and symptomatic changes, it is unnecessary to retreat serofast women exhibiting stable nontreponemal antibody titers during pregnancy.
